BeiGene, Ltd. (ONC)

業務介紹

北京金山藥業有限公司是一家腫瘤學公司,在美國、中國、歐洲和國際上從事癌症患者各種治療的發現和開發。其商業階段產品包括:

1. BRUKINSA,一種布魯頓酪氨酸激酶(BTK)的小分子抑制劑,用於治療各種血液癌症。

2. TEVIMBRA,一種抗PD-1抗體免疫療法,用於治療各種實體瘤和血液癌症。

3. PARTRUVIX,一種選擇性的PARP1和PARP2酶抑制劑,正在作為單一療法和聯合療法評估用於治療各種實體瘤。

該公司的臨床階段產品包括:BGB-11417(Bcl-2抑制劑)、BGB-16673(針對野生型和突變型BTK的嵌合降解激活化合物)、BGB-10188、BGB-21447(Bcl-2抑制劑)、Ociperlimab(TIGIT抑制劑)、Zanidatamab(雙特異性HER2靶向抗體)、Surzebiclimab(TIM-3抑制劑)、BGB-A445(OX40激動抗體)、BGB-15025(HPK1抑制劑)、BGB-24714(SMAC模擬劑)、BGB-26808(HPK-1抑制劑)、Lifirafenib和BGB-3245(RAF抑制劑)、BGB-30813、BGB-A3055(抗CCR8抗體)以及BGB-43395(CDK-4抑制劑)。

該公司還有多個臨床前項目。該公司與Ensem Therapeutics, Inc.、山東綠葉製藥有限公司、Shoreline Biosciences, Inc.、南京利茲生物實驗室有限公司、EUSA Pharma、Assembly Biosciences, Inc.、百奧泰生物技術有限公司、Amgen Inc.和北京諾華製藥有限公司簽有許可協議。北京金山藥業有限公司於2010年成立,總部位於開曼群島的卡曼納灣。



BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

公司網址

https://beonemedicines.com